Rhode Peter 4
4 · HCW Biologics Inc. · Filed Jan 19, 2022
Insider Transaction Report
Form 4
Rhode Peter
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-01-14$0.21/sh+1,714$360→ 48,499 total - Exercise/Conversion
Stock Option Grant (Right to Buy)
2022-01-14−1,714→ 6,857 totalExercise: $0.21Exp: 2030-12-22→ Common Stock (1,714 underlying) - Exercise/Conversion
Common Stock
2022-01-14$0.14/sh+1$0→ 48,500 total - Exercise/Conversion
Stock Option Grant (Right to Buy)
2022-01-14−1→ 51,427 totalExercise: $0.14Exp: 2029-12-19→ Common Stock (1 underlying)
Footnotes (2)
- [F1]20% of the total shares subject to the stock option grant vested on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024, subject to the reporting person's continuous service through the applicable vesting date.
- [F2]These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.